AbbVie’s Rinvoq Achieves Positive Results in Clinical Trials for Crohn’s Disease
July 29, 2022
Trending News ☀️
AbbVie ($NYSE:ABBV) has submitted regulatory applications to the U.S. FDA and the European Medicines Agency seeking approval of Rinvoq for Crohn’s disease. The submissions are supported by data from three phase 3 trials that demonstrated Rinvoq met co-primary endpoints of clinical remission and endoscopic response as induction and maintenance treatment. The positive results from these clinical trials are promising for the potential long-term market and earnings of ABBVIE. If Rinvoq is approved by the FDA and EMA, it would be a significant addition to AbbVie’s current lineup of products. In addition, the data from the clinical trials suggest that Rinvoq could become a standard of care for Crohn’s disease, which would further increase ABBVIE’s market share and earnings.
On Thursday, ABBVIE stock opened at $151.4 and closed at $149.8. This news sent the stock prices up, as investors are confident in the company’s future.
Company’s fundamentals reflect its long term potential, below analysis on ABBVIE are made simple by VI app. According to VI Risk Rating, ABBVIE is a medium risk investment in terms of financial and business aspects. You may look at what are the business and financial areas presenting potential risks in our website.
Abbvie is a research-based biopharmaceutical company that discovers, develops, and markets advanced therapies that address some of the world’s most complex and serious diseases. The company’s products include treatments for cancer, hepatitis C, and HIV/AIDS. Abbvie’s mission is to use its expertise, dedicated people, and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Investing in Abbvie could be a risky but potentially rewarding endeavor. The company is at the forefront of developing innovative treatments for serious diseases, and its products are sold in many countries around the world. While the stock price may be volatile in the short-term, long-term investors may be rewarded as the company continues to develop new treatments and bring them to market.
Leave a Comment